Pheochromocytomas and Paragangliomas Treatment Market Size in 7MM is expected to grow at a decent CAGR by 2034, estimates DelveInsight | Chimerix, Ohara Pharmaceutical, Merck, Novartis, Perspective Therapeutics

DelveInsight's "Pheochromocytomas and Paragangliomas Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of the Pheochromocytomas and Paragangliomas, historical and forecasted epidemiology as well as the Pheochromocytomas and Paragangliomas market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Discover which therapies are expected to grab the Pheochromocytomas and Paragangliomas Market Share @ Pheochromocytomas and Paragangliomas Market Outlook- https://www.delveinsight.com/sample-request/pheochromocytomas-and-paragangliomas-pcpg-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Pheochromocytomas and Paragangliomas Market Report
• In March 2025, Merck Sharp & Dohme LLC announced a study to evaluate the efficacy and safety of belzutifan monotherapy in participants with advanced pheochromocytoma/paraganglioma (PPGL), pancreatic neuroendocrine tumor (pNET), von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Advanced Solid Tumors With hypoxia inducible factor-2 alpha (HIF-2α) related genetic alterations. The primary objective of the study is to evaluate the objective response rate (ORR) of belzutifan per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by blinded independent central review (BICR).
• In March 2025, Perspective Therapeutics announced a study is Phase I/IIa First-in-Human Study of [212Pb]VMT-α-NET Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Neuroendocrine Tumors. This is a prospective, multi-center open-label dose escalation, dose expansion study of [212Pb]VMT-α-NET in up to 160 adult subjects with unresectable or metastatic SSTR2-expressing neuroendocrine tumors (NETs) who have not received prior peptide receptor radionuclide therapy (PRRT).
• The increase in Pheochromocytomas and Paragangliomas Market Size is a direct consequence of the increasing patient population and anticipated launch of emerging therapies in the 7MM.
• As per DelveInsight analysis, the Pheochromocytomas and Paragangliomas Market is anticipated to witness growth at a considerable CAGR.
• The total number of incident cases of PCPG in the 7MM was nearly 4,900 cases in 2024 and are projected to increase during the forecasted period.
• In 2024, it has been observed that germline/somatic mutations are present in nearly 75% of the cases in the US.
• The total number of incident cases in EU4 and the UK for PCPG was estimated to be nearly 1,800 cases in 2024.
• Among EU4 and the UK, Germany accounted for the highest number of incident cases of pheochromocytoma and paraganglioma, while Spain had the least number of cases, in 2024.
• Among the stage-specific cases, the number of localized PCPG cases was higher than that of metastatic cases in Japan.
• The leading Pheochromocytomas and Paragangliomas Companies such as Chimerix, Ohara Pharmaceutical, Merck, Novartis, Perspective Therapeutics, and others.
• Promising Pheochromocytomas and Paragangliomas Pipeline Therapies such as Lanreotide, Axitinib, Sunitinib, Ultratrace Iobenguane (MIBG) I 131, Lutetium [177Lu] oxodotreotide/dotatate, Anlotinib and Penpulimab, Cabozantinib 40 mg, Belzutifan and others.

Stay ahead in the Pheochromocytomas and Paragangliomas Therapeutics Market with DelveInsight's Strategic Report @ Pheochromocytomas and Paragangliomas Market Outlook- https://www.delveinsight.com/sample-request/pheochromocytomas-and-paragangliomas-pcpg-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Pheochromocytomas and Paragangliomas Epidemiology Segmentation in the 7MM
The epidemiology section of Pheochromocytomas and Paragangliomas offers insights into both historical and current patient populations, as well as forecasted trends across seven major countries. This section aids in understanding the factors behind present and projected trends through analysis of various studies and input from key opinion leaders. Additionally, this portion of the market report provides information on the diagnosed patient pool, trends, and underlying assumptions.
• Pheochromocytomas and Paragangliomas Incident Cases
• Pheochromocytomas and Paragangliomas Occurrence or Absence of mutation
• Pheochromocytomas and Paragangliomas Age-specific Cases
• Pheochromocytomas and Paragangliomas Stage-specific Cases

Download the report to understand which factors are driving Pheochromocytomas and Paragangliomas Epidemiology trends @ Pheochromocytomas and Paragangliomas Prevalence- https://www.delveinsight.com/sample-request/pheochromocytomas-and-paragangliomas-pcpg-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Marketed Pheochromocytomas and Paragangliomas Drugs
• DEMSER Capsule 250 mg (metyrosine): Bausch Health and Ono Pharmaceutical
DEMSER is a promising drug with efficacy in the improvement of the symptoms in patients who are not able to sufficiently control the symptoms with sympatholytic drugs. DEMSER is indicated in the treatment of patients with pheochromocytoma for preoperative preparation of patients for surgery, management of patients when surgery is contraindicated and chronic treatment of patients with malignant pheochromocytoma. DEMSER (ONO-5371) was approved and launched in the United States in 1979 for the treatment of pheochromocytoma.In January 2019, Ono Pharmaceutical received manufacturing and marketing approval in Japan for DEMSER capsule for improvement of the status of catecholamine excess secretion in patients with pheochromocytoma. In July 2020, the US FDA approved Amneal Pharmaceuticals' generic version of DEMSER (metyrosine) oral capsules. Amneal's generic is the first for DEMSER to be approved in the United States.

Emerging Pheochromocytomas and Paragangliomas Drugs

• ONC201: Chimerix
ONC201, also called dordaviprone, is a first-in-class small molecule imipridone that selectively binds to the G-protein coupled dopamine receptor D2 (DRD2) and the mitochondrial protease ClpP. ONC201 has been evaluated in an open-label Phase II investigator-initiated study that treated 30 patients at the Cleveland Clinic with rare neuroendocrine tumors. Paraganglioma patients were enrolled in two cohorts initiating ONC201 either once or twice weekly. ONC201 interim efficacy results in dopamine-secreting tumors outside the brain showed 50% ORR in paraganglioma. Investigator-assessed data from this study were presented at the annual meeting of the American Society of Clinical Oncology (ASCO) in 2021 and published in the journal Clinical Cancer Research in 2022.

• WELIREG (belzutifan/MK-6482): Merck
WELIREG is a novel, potent and selective inhibitor of HIF-2a. WELIREG is indicated for von Hippel-Lindau (VHL) disease who need treatment for a type of kidney cancer called Renal Cell Carcinoma (RCC), tumors in the brain and spinal cord called Central Nervous System (CNS) hemangioblastomas, or a type of pancreatic cancer called pancreatic Neuroendocrine Tumors (pNET), that do not require surgery right away, and kidney cancer that has spread (advanced RCC) following treatment with a PD-1 or PD-L1 and VEGF cancer medicines.

To learn more about Pheochromocytomas and Paragangliomas treatment guidelines, visit @ Pheochromocytomas and Paragangliomas Treatment Market Landscape- https://www.delveinsight.com/sample-request/pheochromocytomas-and-paragangliomas-pcpg-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Pheochromocytomas and Paragangliomas Market Outlook
For localized PCPG, surgery remains the mainstay of treatment. In cases of advanced or metastatic disease, treatment options include symptomatic therapy (alpha-blockers, beta-blockers, and catecholamine synthesis inhibitors) for functional PCPG in order to prevent life-threatening events. Additionally, systemic treatments like chemotherapy, targeted therapies, Somatostatin Analogs (SSAs), radiometabolic therapy, and loco-regional procedures such as cytoreductive surgery, external beam radiotherapy, arterial embolization, cryotherapy, and radiofrequency ablation are considered.

Pheochromocytomas and Paragangliomas Drugs Uptake
The drug chapter of the Pheochromocytomas and Paragangliomas report provides a comprehensive analysis of both marketed drugs and late-stage pipeline drugs for this condition. It delves into the details of clinical trials, pharmacological actions, agreements, collaborations, approvals, patents, and advantages, and disadvantages of each drug, as well as the latest news and press releases related to Pheochromocytomas and Paragangliomas.

Major Pheochromocytomas and Paragangliomas Companies
Chimerix, Ohara Pharmaceutical, Merck, Novartis, Perspective Therapeutics, and others.

Learn more about the FDA-approved drugs for Pheochromocytomas and Paragangliomas @ Drugs for Pheochromocytomas and Paragangliomas Treatment- https://www.delveinsight.com/sample-request/pheochromocytomas-and-paragangliomas-pcpg-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Pheochromocytomas and Paragangliomas Market Report
• Coverage- 7MM
• Study Period- 2020-2034
• Pheochromocytomas and Paragangliomas Companies- Chimerix, Ohara Pharmaceutical, Merck, Novartis, Perspective Therapeutics, and others.
• Pheochromocytomas and Paragangliomas Pipeline Therapies- Lanreotide, Axitinib, Sunitinib, Ultratrace Iobenguane (MIBG) I 131, Lutetium [177Lu] oxodotreotide/dotatate, Anlotinib and Penpulimab, Cabozantinib 40 mg, Belzutifan and others.
• Pheochromocytomas and Paragangliomas Market Dynamics: Pheochromocytomas and Paragangliomas Market Drivers and Barriers
• Pheochromocytomas and Paragangliomas Market Access and Reimbursement, Unmet Needs and Future Perspectives

Discover more about Pheochromocytomas and Paragangliomas Drugs in development @ Pheochromocytomas and Paragangliomas Clinical Trials Assessment- https://www.delveinsight.com/sample-request/pheochromocytomas-and-paragangliomas-pcpg-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Key Insights
2. Pheochromocytomas and Paragangliomas Executive Summary
3. Pheochromocytomas and Paragangliomas Competitive Intelligence Analysis
4. Pheochromocytomas and Paragangliomas: Market Overview at a Glance
5. Pheochromocytomas and Paragangliomas: Disease Background and Overview
6. Patient Journey
7. Pheochromocytomas and Paragangliomas Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Pheochromocytomas and Paragangliomas Unmet Needs
10. Key Endpoints of Pheochromocytomas and Paragangliomas Treatment
11. Pheochromocytomas and Paragangliomas Marketed Products
12. Pheochromocytomas and Paragangliomas Emerging Therapies
13. Pheochromocytomas and Paragangliomas: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Pheochromocytomas and Paragangliomas Market Outlook
16. Access and Reimbursement Overview of Pheochromocytomas and Paragangliomas
17. KOL Views
18. Pheochromocytomas and Paragangliomas Market Drivers
19. Pheochromocytomas and Paragangliomas Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight

List of Top Selling Market Research Reports in 2025

Autosomal Dominant Polycystic Kidney Disease Market- https://www.delveinsight.com/report-store/autosomal-dominant-polycystic-kidney-disease-market
Familial Lipoprotein Lipase Deficiency Pipeline- https://www.delveinsight.com/report-store/familial-lipoprotein-lipase-deficiency-pipeline-insight
Frontotemporal Dementia Pipeline- https://www.delveinsight.com/report-store/frontotemporal-dementia-pipeline-insight
Human Papillomavirus-positive Oropharyngeal Cancer Market- https://www.delveinsight.com/report-store/human-papillomavirus-positive-oropharyngeal-cancer-market
Moderate And Severe Chronic Kidney Disease Market- https://www.delveinsight.com/report-store/chronic-kidney-disease-chronic-renal-failure-market
Monoclonal Gammopathy Of Undetermined Significance Market- https://www.delveinsight.com/report-store/monoclonal-gammopathy-of-undetermined-significance-market
Myopia Treatment Devices Market- https://www.delveinsight.com/report-store/myopia-treatment-devices-market
Myotonic Dystrophy Market- https://www.delveinsight.com/report-store/myotonic-dystrophy-market
Neurodermatitis Market- https://www.delveinsight.com/report-store/neurodermatitis-market
Osteochondrodysplasia Market- https://www.delveinsight.com/report-store/osteochondrodysplasia-market
Peptic Ulcer Hemorrhage Market- https://www.delveinsight.com/report-store/peptic-ulcer-hemorrhage-market
Perivascular Epithelioid Cell Tumor Market- https://www.delveinsight.com/report-store/perivascular-epithelioid-cell-tumor-market
Plasmodium Vivax Malaria Market- https://www.delveinsight.com/report-store/plasmodium-vivax-malaria-market
Thymidine Kinase 2 Deficiency Market- https://www.delveinsight.com/report-store/thymidine-kinase-2-deficiency-tk2d-market
Xlinked Severe Combined Immunodeficiency Market- https://www.delveinsight.com/report-store/xlinked-severe-combined-immunodeficiency-scid-market
Chagas Disease Market - https://www.delveinsight.com/report-store/chagas-disease-market
Diabetes Insipidus Market- https://www.delveinsight.com/report-store/diabetes-insipidus-market
Geographic Atrophy Market- https://www.delveinsight.com/report-store/geographic-atrophy-ga-market
Peanut Allergy Market Report- https://www.delveinsight.com/report-store/peanut-allergy-market
Postherpetic Neuralgia Market- https://www.delveinsight.com/report-store/postherpetic-neuralgia-market
Pouchitis Market- https://www.delveinsight.com/report-store/pouchitis-market
Presbyopia Market- https://www.delveinsight.com/report-store/presbyopia-market
Prostate Cancer Market- https://www.delveinsight.com/report-store/prostate-cancer-market-insight
Refractory Metastatic Melanoma Market- https://www.delveinsight.com/report-store/refractory-metastatic-melanoma-market
Rubella Market- https://www.delveinsight.com/report-store/rubella-market
Smoking Cessation And Nicotine Addiction Market- https://www.delveinsight.com/report-store/smoking-cessation-and-nicotine-addiction-market
Systemic Inflammatory Response Syndrome Market- https://www.delveinsight.com/report-store/systemic-inflammatory-response-syndrome-market
Systemic Inflammatory Response Syndrome Market Insights- https://www.delveinsight.com/report-store/systemic-inflammatory-response-syndrome-market
Uveal Melanoma Market- https://www.delveinsight.com/report-store/ocular-melanoma-market
Wiskott-aldrich Syndrome Market- https://www.delveinsight.com/report-store/wiskott-aldrich-syndrome-market
Adult T-cell Leukemia-lymphoma Market- https://www.delveinsight.com/report-store/adult-t-cell-leukemia-lymphoma-market
Artificial Disc Market- https://www.delveinsight.com/report-store/artificial-disc-market
Asperger Syndrome Market- https://www.delveinsight.com/report-store/asperger-syndrome-market
House Dust Mite Allergy Market- https://www.delveinsight.com/report-store/house-dust-mite-allergy-market
Immune Thrombocytopenia Market- https://www.delveinsight.com/report-store/immune-thrombocytopenia-itp-market
Keloid Market- https://www.delveinsight.com/report-store/keloid-market
Pcsk9 Market- https://www.delveinsight.com/report-store/pcsk9-inhibitors-psck9i-market
Peripheral Nerve Repair Devices Market- https://www.delveinsight.com/report-store/peripheral-nerve-repair-devices-market
Sarcopenia Market- https://www.delveinsight.com/report-store/sarcopenia-market
Skin Neoplasm Market- https://www.delveinsight.com/report-store/skin-neoplasms-market
Vascular Imaging Devices Market- https://www.delveinsight.com/report-store/vascular-imaging-market-market
Venous Ulcer Market- https://www.delveinsight.com/report-store/venous-leg-ulcer-market
Cardiogenic Shock Market- https://www.delveinsight.com/report-store/cardiogenic-shock-market
Herpes Labialis Market- https://www.delveinsight.com/report-store/herpes-labialis-market
Meningococcal Meningitis Market- https://www.delveinsight.com/report-store/meningococcal-meningitis-market
Septic Shock Market- https://www.delveinsight.com/report-store/septic-shock-market
Transmucosal Drug Delivery Devices Market- https://www.delveinsight.com/report-store/transmucosal-drug-delivery-devices-market
Carcinoid Syndrome Market- https://www.delveinsight.com/report-store/carcinoid-tumor-market
Cone Rod Dystrophy Market- https://www.delveinsight.com/report-store/cone-rod-dystrophy-market
Orthopedic Power Devices Market- https://www.delveinsight.com/report-store/orthopedic-power-devices-market
Tendonitis Market- https://www.delveinsight.com/report-store/tendonitis-market
Diabetic Retinopathy Market- https://www.delveinsight.com/report-store/diabetic-retinopathy-market
Hydrocephalus Treatment Market- https://www.delveinsight.com/report-store/hydrocephalus-market
Short Bowel Syndrome Drug Market- https://www.delveinsight.com/report-store/short-bowel-syndrome-market
Spinal Trauma Devices Market- https://www.delveinsight.com/report-store/spinal-trauma-devices-market-market
Ventral Hernia Market- https://www.delveinsight.com/report-store/ventral-hernia-market
Tcr Therapy Market- https://www.delveinsight.com/report-store/tcr-therapy-market
Heart Failure Market- https://www.delveinsight.com/report-store/congestive-heart-failure-market
Surgical Robotic System Market- https://www.delveinsight.com/report-store/surgical-robotic-system-market
Thyroid Cancer Market- https://www.delveinsight.com/report-store/thyroid-cancer-market
Indwelling Catheters Market- https://www.delveinsight.com/report-store/urinary-catheters-market

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Contact Us
Yash Bhardwaj
info@delveinsight.com
https://www.delveinsight.com/

This release was published on openPR.